02.10.2015 Views

studies

2015SupplementFULLTEXT

2015SupplementFULLTEXT

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 783A<br />

ropoietin. Among pts receiving TPV+pegIFN/RBV, 12 (10%)<br />

were transfused and 1 received erythropoietin due to anemia.<br />

Conclusions: In MALACHITE-I and MALACHITE-II, 3D+/-RBV<br />

had more favorable AE profiles than TPV+pegIFN/RBV. With<br />

3D+/-RBV, anemia was less frequent and less severe, and<br />

never required transfusion or use of erythropoietin. RBV was<br />

better tolerated in the context of newer DAAs than of TPV and<br />

pegIFN.<br />

Adverse events and hemoglobin decreases in MALACHITE-I and<br />

MALACHITE-II.<br />

*P1755μg.h/L after the first dose is predictive of sustained virological<br />

response (SVR) in HCV-patients treated with peginterferon/RBV*.<br />

The aim of this study was to test the clinical benefit<br />

of RBV early dose adjustment based on this threshold (Bayesian<br />

estimation) in under-exposed naïve genotype 1-infected<br />

patients. Methods: multicenter, randomized, controlled trial<br />

with two parallel groups; SC-group: standard of care in 2010-<br />

2011, i.e. peginterferon-α2a 180μg/week and weight-based<br />

RBV 1000-1200mg/day during 48 weeks; AD-group: personalized<br />

increase of RBV dose if D0AUC 0-4H<br />

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!